SEONGNAM, SOUTH KOREA — South Korean biotechnology company Rznomics has received an additional research payment from Eli Lilly and Company under the companies’ ongoing collaboration to develop RNA-editing therapies for hereditary hearing loss, according to multiple Korean media reports citing the company....
No actionable change — this is early-stage industry funding news with no clinical data or approved treatment.
Continued pharma investment in RNA-editing for hereditary hearing loss signals growing industry confidence in gene-based hearing therapies, though clinical translation remains years away.
- 01Eli Lilly made an additional research payment to Rznomics under an existing collaboration agreement.
- 02The program targets hereditary (genetic) hearing loss using RNA-editing technology.
- 03RNA editing modifies genetic messages inside cells without permanently altering DNA.
- 04No clinical trial data or human efficacy results were reported.
- 05The milestone reflects pipeline progress but no product is near regulatory submission.
Rznomics received an additional research payment from Eli Lilly under their collaboration agreement.
press releasesupportedThe collaboration is aimed at developing RNA-editing therapies for hereditary hearing loss.
press releasesupported